AMARIN CORP PLC\UK Repayments of Convertible Debt
AMARIN CORP PLC\UK (AMRN) reported Repayments of Convertible Debt of $15.11 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2019-02-27
- AMARIN CORP PLC\UK repayments of convertible debt for the quarter ending 2017-12-31 was $0.00.
- AMARIN CORP PLC\UK repayments of convertible debt for the quarter ending 2017-09-30 was $0.00.
- AMARIN CORP PLC\UK repayments of convertible debt for the quarter ending 2017-06-30 was $0.00.
- AMARIN CORP PLC\UK repayments of convertible debt for the quarter ending 2017-03-31 was $15.11M.
- AMARIN CORP PLC\UK repayments of convertible debt for fiscal 2017 was $15.11M.
- AMARIN CORP PLC\UK repayments of convertible debt for fiscal 2015 was $16.14M.
- AMARIN CORP PLC\UK repayments of convertible debt for fiscal 2009 was $2.00M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 derived: sum of 3 quarters · filed 2019-02-27 | $15.11M 10-K · filed 2019-02-27 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $15.11M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $15.11M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $15.11M 10-Q · filed 2018-05-02 | |||
| 2015-12-31 | $16.14M 10-K · filed 2018-02-27 | |||
| 2009-12-31 | $2.00M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |